Literature DB >> 3285267

The nitrite and leukocyte esterase tests for the evaluation of asymptomatic bacteriuria in obstetric patients.

A W Robertson1, P Duff.   

Abstract

The purpose of this investigation was to compare the reliability of a urine dipstick evaluation for nitrites and leukocyte esterase activity with that of a urine culture in diagnosing asymptomatic bacteriuria in obstetric patients. A clean-catch midstream urine specimen was obtained from 750 consecutive obstetric patients presenting for initial evaluation. One portion of the specimen was tested for nitrites and leukocyte esterase activity with Chemstrip LN dipsticks. A second aliquot of urine was plated on blood and MacConkey agar and incubated aerobically. The cost of the nitrite and leukocyte esterase test was $0.35. The per patient charge for the urine cultures would have been $28. Sixty-two women (8.3%) had urine cultures of 100,000 or more colony-forming units of a uropathogen per milliliter. The sensitivities of the nitrite and leukocyte esterase test in identifying patients with positive cultures were 43 and 77%, respectively, and the specificities were 99 and 96%, respectively. The sensitivity and specificity for the two tests combined (either test abnormal) were 92 and 95%, respectively. Five patients had negative screening tests but positive urine cultures; all five isolates were gram-positive organisms, three group B streptococci and two enterococci. We conclude that neither the nitrite test nor the leukocyte esterase test alone is a sensitive enough screening test to detect asymptomatic bacteriuria in obstetric patients. The combination of the two tests, however, may provide an acceptable cost-effective alternative to screening all asymptomatic obstetric patients with urine cultures.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3285267

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

1.  Usefulness of urine dipstick in an urogynecologic population.

Authors:  Fareesa Raza-Khan; Kim Kenton; Susan Shott; Linda Brubaker
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-01-12

Review 2.  Management of urinary tract infections in pregnancy: a review with comments on single dose therapy.

Authors:  S H Zinner
Journal:  Infection       Date:  1992       Impact factor: 3.553

3.  Systemic alterations induced by phospholipase A2 , BmooTX-I, isolated from Bothrops moojeni snake venom.

Authors:  Kellen Cristina Torres Costa; Bruna Barbosa de Sousa; Edigar Henrique Vaz Dias; Déborah Fernanda da Cunha Pereira; Mariana Santos Matias; Wilson Júnior Oliveira; Antônio Vicente Mundim; Carla Cristine Neves Mamede; Luíz Fernando Moreira Izidoro; Júnia de Oliveira Costa; Fábio de Oliveira
Journal:  Int J Exp Pathol       Date:  2018-11-20       Impact factor: 1.925

Review 4.  Pyelonephritis in pregnancy: an update on treatment options for optimal outcomes.

Authors:  Jennifer A Jolley; Deborah A Wing
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

Review 5.  Pyelonephritis in pregnancy: treatment options for optimal outcomes.

Authors:  D A Wing
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer.

Authors:  J B Andersen; M Aaboe; E C Borden; O G Goloubeva; B A Hassel; T F Orntoft
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

Review 7.  Unmet Need of Antenatal Screening for Asymptomatic Bacteriuria: A Risk Factor for Adverse Outcomes of Pregnancy.

Authors:  Manish Gehani; Suman Kapur; Pankaj Bhardwaj; Vijayalakshmi Nag; Sudharsanam Manni Balasubramaniam; Nagamani Kammili; Sudha D Madhuri
Journal:  Indian J Community Med       Date:  2019 Jul-Sep

8.  Leukocyte esterase activity in vaginal fluid of pregnant and non-pregnant women with vaginitis/vaginosis and in controls.

Authors:  Per-Anders Mårdh; Natalia Novikova; Ola Niklasson; Zoltan Bekassy; Lennart Skude
Journal:  Infect Dis Obstet Gynecol       Date:  2003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.